title: Modified recombinant adenoviruses increase porcine circovirus 2 capsid protein expression and induce enhanced immune responses in mice.
abstract: Porcine circovirus type 2 (PCV2) is the primary viral pathogen of porcine circovirus associated disease (PCVAD) and vaccination is an important method to prevent and control the disease. The expression of PCV2 capsid protein (Cap) in adenovirus vector system has been investigated, but the poor immune responses limit its application. In this study, transcriptional enhancer element largest intron of the human cytomegalovirus (Intron A) and woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) were applied to increase the immunogenicity of PCV2 Cap adenovirus-based vaccine. Western blot and indirect immunofluorescence assay (IFA) analysis showed that modified adenoviruses with Intron A and WPRE alone or both could significantly increase the expression of Cap compared to the unmodified adenoviruses. Furthermore, the humoral and cellular immune responses of the constructed recombinant adenoviruses were evaluated in mice. Indirect ELISA, virus neutralizing test and western blot showed that modified adenoviruses elicited higher humoral immune responses than unmodified adenovirus, and Intron A-WPRE-modified virus immunized group had better immune response than the others. Besides, the results of lymphocyte proliferation response and cytokines release assay showed that enhanced cellular immune responses were induced by modified adenoviruses. These results demonstrated that Intron A and WPRE significantly improved the expression of the Cap protein in adenovirus vector system and enhanced the immune responses in mice, making the adenovirus vector system more applicable against PCV2.
authors.forename: D L
authors.initials: DL
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
authors.forename: L L
authors.initials: LL
authors.lastname: Chang
authors.forename: Q
authors.initials: Q
authors.lastname: DU
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: T T
authors.initials: TT
authors.lastname: Wang
authors.forename: X M
authors.initials: XM
authors.lastname: Luo
authors.forename: X M
authors.initials: XM
authors.lastname: Zhao
authors.forename: D W
authors.initials: DW
authors.lastname: Tong
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000502:physiology*; D002460:Cell Line; D049109:Cell Proliferation; D018173:Circoviridae Infections / Q000517:prevention & control / Q000821:virology; D017925:Circovirus / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D015967:Gene Expression Regulation, Viral / Q000502:physiology; D057809:HEK293 Cells; D006801:Humans; D008214:Lymphocytes / Q000502:physiology / Q000821:virology; D051379:Mice; D013552:Swine; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D016207:Cytokines; D014765:Viral Vaccines
keywords: modified recombinant adenoviruses; porcine circovirus type 2; capsid protein; immune responses.